Welcome to the first issue of the new Clinical & Translational Metabolism. It is my privilege and honor to serve as the editor-in-chief and establish this journal as an integrative venue for high-quality research from clinical and translational science in all areas of metabolism. In addition to classical aspects of metabolism such as the biochemical and physiological processes that underlie energy homeostasis and the regulation of nutrient balance, the journal also seeks to highlight advances in the integration of these areas in the broader context of whole organism physiology and clinical medicine from areas including cancer, mitochondrial diseases, cardiovascular health, musculoskeletal health, endocrinology, regenerative medicine, and beyond.

As we consider this exciting future, it is appropriate to reflect on the journey that led to this point. Over the last few months, the journal has recruited an editorial board of distinguished professionals from across the world. Additionally, we have hired four associate editors who will help lead to journal to fulfilling its goals: Dr. Rachelle Johnson (Vanderbilt University Medical Center, USA), Dr. Ryszard Nosalksi (University of Edinburgh, UK), Dr. Gary Patti (Washington University in St. Louis, USA), and Dr. Masanari Kuwabara (Toranomon Hospital, Japan).

Moreover, Clinical & Translational Metabolism is not starting from scratch but is instead the next step in the more than 20-year history of Clinical Reviews in Bone & Mineral Metabolism (CRBMM). CRBMM’s first issue was published in 2002 and the journal aimed to fill a niche of review articles bridging basic and clinical science into the context of clinical practice in bone and mineral metabolism. Under the stewardship of a talented editorial board who supported four successive editors-in-chief—Angelo Licata, Matthew Allen, Kurt Hankenson, and this author—it was host to more than 400 articles across dozens of special collections. Speaking as a CRBMM reader, contributor, editorial board member, and its last editor-in-chief, I think it safe to say that CRBMM fulfilled its goal.

One might ask: why re-launch CRBMM as Clinical & Translational Metabolism? First, it is worth noting that today’s field of bone and mineral metabolism is vastly different than that of 2002. In fact, looking across the last 10 years of CRBMM, the article titles reflect a broadening scope and inclusion of research areas beyond strictly mineralized tissues and homeostasis thereof. The more general scope of Clinical & Translational Metabolism recognizes that metabolism research is an integrative field whose search for answers spans multiple systems and contexts.

Second, CRBMM’s focus on review articles limited the opportunity for the journal to present the most recent advances. Instead, Clinical & Translational Metabolism will support a wide variety of article types including original research (such as single observations, null results, and replication studies), commentaries, editorials, case reports/series, and reviews. This full spectrum approach affords greater flexibility as the journal helps advance our understanding of metabolic processes that underlie health and disease.

Finally, I wish to note one tradition that CRBMM adhered to in its earliest years which Clinical & Translational Metabolism will rekindle: the coupling of particularly noteworthy articles with commentaries or editorials to help highlight them and place them in a broader context. This approach will allow us to help bring visibility to studies which might otherwise be overlooked. It is also a means to provide additional opportunities for early-career and mid-career researchers to share their thoughts and establish presence in their fields.

On behalf of the entire editorial team, I am pleased to invite you to join us as a contributor and/or reviewer. With capable support and collaboration from Springer Nature, the future for Clinical & Translational Metabolism is bright indeed.